Type 1 diabetes (T1D) is a chronic autoimmune disease in which autoreactive T-cells and inflammation cause severe loss of pancreatic beta cells. Insulitis, the pathologic hallmark of T1D, is an inflammatory lesion consisting of immune cell infiltrates around and within the islets. New research initiatives and methodologies are advancing our understanding of pancreas pathology. Studies have revealed the predominant cellular types that infiltrate the islets, novel molecular aspects associated with insulitis, and the coexistence of additional pathological abnormalities. While insulitis is a critical element of T1D pathology and pathogenesis, it is typically present only in a modest proportion of islets at any given time, even at diagnosis, with overall limited relation to disease duration. Thus, the relative importance of insulitis as a determining factor of diabetes symptoms at disease onset appears to have been overestimated; growing evidence also shows that beta cell loss at diagnosis is more modest than previously thought. Thus, the sole targeting of the immune system may not afford full therapeutic efficacy if dysfunction affects beta cells that are not under immune attack and this is a key contributor to symptoms. Combination therapies that promote both immunoregulation and address beta cell dysfunction should be more effective in treating this chronic disease process. It remains a major goal to clarify the relation of insulitis with the dynamics of beta cell loss and coexisting mechanisms of dysfunction, according to clinical stage; such improved understanding is key to design therapeutic strategies that target multiple pathogenic mechanisms.
cells. Although Gepts described insulinitis more than 60 yr ago (7), studies of insulinitis and other features of pancreas pathology in T1D have been limited by the scarce access to pancreata from T1D patients. The most extensive information about T1D pancreas pathology derives from the study of autopsy specimens obtained from patients near the time of diagnosis in the UK (8) and of biopsy specimens of living patients [the (Diabetes Virus Detection) DiViD Study from Norway, and earlier studies from Japan] (9, 10); during the last decade, the Juvenile Diabetes Research Foundation (JDRF) has supported the launch of an organized effort in the USA, (nPOD), to recover pancreas and other tissues from organ donors with T1D (11). This effort has allowed examining the pancreas with T1D throughout a much wider range of disease duration (12).

A consensus definition of the insulinitis lesion has been recently reported and should help focusing research efforts in the future (13); key elements of this definition are the presence of a predominantly lymphocytic infiltration of the islets of Langerhans, consisting of at least 15 CD45+ cells/islet and present in a minimum of three islets. Insulitis can be found in the islet periphery (peri-insulitis, often showing focal aggregation at one pole of the islet and in contact with the islet periphery) or within the islet parenchyma (intra-insulitis); several studies indicate that the predominant form of insulinitis in the human pancreas is peri-insulitis, and it is much less severe than in experimental mouse models (12, 14, 15). Insulitis is most often detected in islets containing insulin-positive beta cells, but critically the same pancreas will also show pseudo-atrophic islets devoid of insulin-positive cells.

**Characteristics of the insulinitis**

Investigators have examined the relative proportions of various infiltrating cell types in the insulinitis lesion and suggest that heterogeneous profiles may underlie disease severity and progression. While both T and B lymphocytes are reported in insulinitis lesions, cytotoxic CD8 T-cells appear to be the predominant population and could target beta cells expressing elevated levels of Human Leucocyte Antigen (HLA) class I molecules (8, 16–18); of note, hyper-expression of class I molecules (and class II molecules) may be associated with viral infections postulated to play a key role in T1D pathogenesis (19). Hyper-expression of HLA molecules represents another key feature in the pathology of the T1D that highlights a chronic inflammatory state; this is often associated with insulinitis (20). It is presently unknown whether islet-infiltrating CD8 T-cells can target viral epitopes presented by infected beta cells on their HLA class I molecules. However, studies of nPOD pancreata have demonstrated autoantigen-specific T-cells in the insulinitis lesion (21); these observations directly connect those autoreactive CD8 T-cells to the insulinitis and to disease pathogenesis. These studies also compared the diversity of the islet-infiltrating T-cell populations in relation to T1D duration, and reported increased diversity in the antigen specificity of the infiltrating CD8 T-cells in patients with longer disease duration. Thus, the autoimmune response appears to evolve with time, even after diagnosis; these results also provide evidence for the chronicity of the process.

Two distinct patterns of insulinitis were described in autopsy samples from UK patients with recent onset T1D according to the prevalence of CD20 B-cells (CD20Hi and CD20Lo) (22); these findings were replicated in the nPOD and DiViD cohorts (23); the CD20Hi profile appears associated with an early age of diagnosis (7 yr) while those diagnosed after age 13 have a CD20Lo insulinitis. Thus, the presence of higher proportions of B-cells in the insulinitis lesion may be a marker of early triggering of autoimmunity or of a more rapid rate of beta cell loss.

The study of nPOD pancreata has identified some key molecular changes typical of insulinitis: these include the accumulation of hyaluronan, a key constituent of the extra-cellular matrix, and hyaluronan binding proteins, around islet cells and infiltrating lymphocytes in islets affected by insulinitis (24). These molecules may play a role in insulinitis by promoting lymphocyte adhesion and migration, and antagonizing hyaluronan deposition prevents diabetes in experimental mice (25–27). Moreover, cathepsins were found in the insulinitis lesion near the areas of disruption of the peri-islet basement membrane, and may favor the penetration of lymphocytes inside the islets (28).

**Insulitis in human type 1 diabetes**

Overall, the proportion of islets showing insulinitis in the human T1D pancreas is quite low (∼10–30%); this may vary to some extent by age and disease duration. Insulitis appears more prevalent in younger patients and those whose pancreas was examined nearer to diagnosis. For example, reports indicate that about 30% of insulin-positive islets are infiltrated in young patients who were recently diagnosed (6). In a study of biopsies performed in six patients with recent onset T1D (DiViD Study), aged 24–25 yr, the proportions of islets affected by insulinitis varied significantly, ranging between 5 and 58%; of note, only one of the six patients had greater than 50% of the islets affected by insulinitis, and that occurred in one of the two sections analyzed (9, 14); on average, only 11% of the islets examined had insulinitis. Among 80 nPOD organ donors with variable duration of T1D, 17 had insulinitis with disease duration extending from diagnosis to 12 yr, and age of onset ranging...
between 4 and 28 yr. The frequency of insulitis had limited inverse correlation with diabetes duration and no correlation with age at onset, or age at demise. Insulitis predominantly affected insulin-positive islets (33% vs. only 2% of insulin-negative islets). Importantly, insulitis was observed in many patients, as well as residual beta cells, even many years after diagnosis (12).

Collectively, the available findings emphasize the chronicity of islet autoimmunity, which is present for several years after diagnosis in both children and young adults. All studies concur that insulitis does not affect all islets at the same time, suggesting that this is a process that evolves over time. Moreover, both a meta-analysis of earlier data (29, 30) and recent findings argue that the long held belief that 90% of the beta cell mass is lost at diagnosis is no longer a tenable concept. Younger children are expected to have a greater loss, but those diagnosed when teenagers or older were reported to have at least 40–60% of their islets staining positive for insulin (23, 29), including results from the UK, nPOD and DiViD cohorts. Six DiViD biopsies were performed in adult patients with recent onset T1D: insulin staining was found in 18–66% and on average in 36% of the islets examined (14). In the analysis of the 80 T1D nPOD donors, of whom only a few had disease duration less than 1 yr (12), residual beta cells were observed in all T1D donors with insulitis, who had, on average, a roughly 10-fold higher beta cell mass compared with those without insulitis; there was no correlation of beta cell mass with insulitis, disease duration and age of onset.

Thus, there appears to be some disconnect between the severe diabetes symptoms and impairment of insulin secretion at diagnosis and the emerging evidence suggesting limited insulitis and only partial physical beta cell loss. This limited pathology has also been noted in recipients of pancreas transplants who had developed T1D recurrence in their grafts (31). There is increasing evidence that inflammation and beta cell dysfunction may be important pathogenic mechanisms at the time of initial disease manifestation and contribute to cause the symptoms of severe hyperglycemia (32–36). Moreover, islet function may be recoverable (32), as shown by the DiViD study: islets isolated from the pancreas obtained via biopsy in newly diagnosed T1D recovered function in culture. This recognition has important implications for the design of therapeutic strategies to reverse diabetes at diagnosis. In fact, the low prevalence of insulitis at diagnosis suggests that even at that time, a therapy that attempts to deplete autoreactive T-cells may only be treating those islets with insulitis, and therefore therapeutic efficacy may be limited. Combinatorial therapies should therefore address pathogenic cofactors, attempt to mitigate inflammation and correct beta cell dysfunction (37).

The above findings also suggest that beta cell destruction is quite heterogeneous and is not likely to be completed until several years after diagnosis. Studies have reported persistence of insulin-positive beta cells even decades after diagnosis (38–40) and that glucose transporters continue to be expressed (21, 41). There is evidence in some patients with long disease duration that beta cells express the survivin molecule, possibly a factor in the persistence of the beta cell phenotype (42). Low levels of beta cell apoptosis have been noted in the pancreas of patients with long disease duration, implying the existence of some beta cell turnover (38–40). The above observations are usually in the context of chronic signs of islet inflammation, including insulitis and increased expression of HLA class I molecules (20).

Concordant with these observations, the assessment of functional beta cell mass through metabolic testing shows that stimulated C-peptide responses are often partially reduced in living patients (43–47), again with younger children showing more severe impairment. A prospective, postdiagnosis evaluation of C-peptide responses is being conducted in newly diagnosed patients by the T1D TrialNet; results so far have shown significant persistence of C-peptide, with about 80% of patients at 1 yr and 60% at 2 yr responding to a mixed meal with a peak C-peptide that would be suitable for randomization in a clinical trial at diagnosis; there is a slower decline in the second year after diagnosis, and not all patients experienced further decline of C-peptide secretion during the follow-up period (46). Several studies have reported that patients with decades of disease duration may secrete low amount of C-peptide and also respond with increased levels to stimulation (40, 48–50). Thus, both pathology data about insulitis and beta cell mass and clinical data suggest that T1D is due to a chronic disease process, which affects islets asynchronously continues its course over a long period of time after diagnosis.

The disease process in preclinical type 1 diabetes

There is much less information regarding the pathology of T1D during the prediabetic period. In fact, the relationships of insulitis to autoantibody conversion and beta cell destruction during the prodromic period are essentially unknown. It would be critically important to establish if insulitis is closely associated with the triggering or autoantibodies and/or circulating autoreactive T-cells; this would be of direct relevance to the design of prevention trials. Given that many individuals express autoantibodies for years prior to the eventual development of
T1D, we need to understand whether this chronicity is due to a slowdestructive process affecting a minority of islets over time or if at some point critical factors act as precipitants and may trigger insulitis at a later stage. Prospective studies in relatives reveal that the triggering of islet autoimmune responses (autoantibodies) is eventually followed by the progressive impairment of insulin secretion and glucose metabolism; however, autoantibody-positive relatives may have normal metabolic measures for years, with abnormalities becoming apparent closer to diagnosis (51–53). Perhaps, the actual destruction of beta cells is a late event that is triggered nearer to diagnosis, and perhaps autoantibody positivity per se does not necessarily imply the presence of insulitis and beta cell loss (54). Such key questions may only be addressed if robust measures of islet inflammation, insulitis, beta cell mass, and death can be developed and applied in longitudinal studies. Addressing these questions will require a combination on laboratory and imaging approaches (55–57).

Efforts are presently ongoing to identify pancreata from general population organ donors who test positive for T1D-associated autoantibodies, to determine the relationship of autoantibody positivity to pancreas pathology and especially the presence or absence of insulitis. Such efforts are quite challenging, as the proportion of autoantibody-positive donors in the general population is very small. After pioneering studies demonstrated the feasibility of screening organ donors for autoantibodies (58, 59), the JDRF nPOD has launched a prospective, large-scale screening effort across the USA (11). So far, pancreata from 18 donors who tested positive for autoantibodies have been recovered, of whom 13 expressed a single autoantibody, typically against the glutamic acid decarboxylase autoantigen (12). Donors with a single autoantibody do not typically carry HLA genes associated with increased T1D risk and do not appear to have insulitis (12, 60). Thus, it is unclear if such donors should be considered as true prediabetic subjects, but there are increasing reports that their pancreas may show other abnormalities (11). nPOD identified five donors with multiple autoantibodies, and two had insulitis in association with high-risk HLA types (12). Parallel efforts in Europe have conducted retrospective autoantibody screening of donors whose pancreas had been used for islet cell isolation, which typically would allow pathology evaluation of a small portion of the pancreas. One such study from Belgium identified 62 autoantibody-positive donors, and insulitis was only found in 2 of the 3 donors with multiple autoantibodies, who also carried high-risk HLA types (61). Another study from Scandinavia identified 32 donors with autoantibodies, 9 of whom had multiple autoantibodies; yet none had high-risk HLA types, and no insulitis was found (62). We know that the presence of multiple autoantibodies is associated with much higher risk of progression to overt disease than positivity for a single autoantibody, and thus these findings may be related to the presence or absence of insulitis. The specificity of the autoimmune response could also be important, but the number of autoantibody-positive donors reported in the literature is too small to fully inform as whether particular autoantibody responses are closely associated with insulitis. There is a need to study more of these rare cases, as the relation between insulitis, beta cell loss, genetic predisposition, and autoantibodies is critical to understand during the prediabetic period. Addressing these questions needs to account for the genetic, environmental, and immunological heterogeneity of T1D.

Conclusions

In closing, the launch of programs aiming at the recovery and study of T1D and autoantibody-positive pancreata is leading to new discoveries about the pathology of human T1D; these findings also help identifying new therapeutic targets. Insulitis remains a key element of T1D pathology, but it needs to be recognized that it is not the only pathogenic element; this has relevance for the design of clinical trials for more effective targeting of pathogenic mechanisms. Combination therapies that promote both immunoregulation and address beta cell dysfunction should be more effective in treating this chronic disease process. Future studies will reveal more of the phenotypic features of infiltrating cells in the insulitis lesion, also in relation to other abnormalities, as well as information about gene expression and epigenetic regulation of the beta cells, which is likely to be a major contributor to their dysfunction and ultimate fate. If the field stays the course, these efforts and improved clinical assessments in natural history studies will advance our understanding of the disease pathogenesis.

Acknowledgements

Studies by the author related to this topic were supported by grants from the National Institutes of Health (R01 DK070011), the JDRF (research grants 25-2013-268, 17-2011-594, 17-2012-3), The Leona M. and Harry B. Helmsley Charitable Trust (George Eisenbarth nPOD Award for Team Science, 2015PG-T1D052) and by the Diabetes Research Institute Foundation, Hollywood, Florida.

References

1. Pugliese A. Advances in the etiology and mechanisms of type 1 diabetes. Discov Med 2014: 18: 141–150.
Insulitis in type 1 diabetes

11. Pugliese A, Cerasi E, Targher G et al. Insulin and autoimmune processes in type 1 diabetes. In situ characterization of autoantibody expression and related phenomena. Autoimmun Rev 2006; 5: 465–477.

12. Ziegler AG, Meier-Stiegen M, Farquharson MA. The histopathology of the pancreas in type 1 diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986: 29: 267–274.

13. Krogvold L, Edwin B, Buanes T et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 2014; 57: 841–843.

14. Imagawa A, Hanafusa T, Tamura S et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001; 50: 1269–1273.

15. Pugliese A, Yang M, Kusmarteva N et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes 2014; 15: 1–9.

16. Campbell-Thompson M, Fu A, Kaddis J et al. Insulitis and beta-cell mass in the natural history of type 1 diabetes. Diabetes 2016; 65: 719–731.

17. Campbell-Thompson ML, Atkinson MA, Butler AE et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia 2013; 56: 2541–2543.

18. Bottazzo GF, Dean BM, McNally JM, Mackay EH, Swift PFG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313: 353–360.

19. Krogvold L, Edwin B, Buanes T et al. Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 2015: 64: 1682–1687.

20. Morgan NG, Leete P, Foullis AK, Richardson SJ. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life 2014; 66: 723–734.

21. Coppieters KT, Dotta F, Amirian N et al. Demonstration of islet-autoreactive CD8 T cells in insulin lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209: 51–60.

22. Arif S, Leete P, Nguyen V et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014: 63: 3835–3845.

23. Leete P, Willcox A, Krogvold L et al. Differential insulitic profiles determine the extent of beta cell destruction and the age at onset of type 1 diabetes. Diabetes 2016; pii: db151615.

24. Bogdani M, Johnson PY, Potter-Perigo S et al. Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulin. Diabetes 2014: 63: 2727–2743.

25. Kupers HF, Reck M, Gurevich I et al. Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and TH1 polarization. Proc Natl Acad Sci USA 2011: 113: 1339–1344.

26. Nagy N, Kaper G, Johnson PY et al. Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulin. J Clin Invest 2015: 125: 3928–3940.

27. Bogdani M, Korpos E, Simeonovic CJ, Parish CR, Sorokin L, Wight TN. Extracellular matrix components in the pathogenesis of type 1 diabetes. Curr Diab Rep 2014; 14: 552.

28. Korpos E, Kadri N, Kappelhoff R et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes 2013: 62: 531–542.

29. Klinke DJ. Extent of Beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008: 3: e1374.

30. Klinke DJ. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS One 2011: 6: e26873.

31. Vendrame F, Pileggi A, Laughlin E et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010: 59: 947–957.

32. Krogvold L, Skog O, Sundstrom G et al. Function of isolated pancreatic islets from patients at onset of type 1 diabetes: insulin secretion can be restored after some days in a nonidiabeticogenic environment in vitro: results from the DiViD study. Diabetes 2015: 64: 2506–2512.

33. Marifour I, Lopez XM, Lefkaiditis D et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia 2012: 55: 2417–2420.
Pugliese

34. IMAI Y, DOBRIAN AD, MORRIS MA, TAYLOR-FISHWICK DA, NADLER JL. Lipids and immunoinflammatory pathways of beta cell destruction. Diabetologia 2016: 59: 673–678.

35. BURCH TC, MORRIS MA, CAMPBELL-THOMPSON M, PUGLIESE A, NADLER JL, NYALWIDHE JO. Proteomic analysis of disease stratified human pancreas tissue indicates unique signature of type 1 diabetes. PLoS One 2015: 10: e0135663.

36. GRZESIK WJ, NADLER JL, MACHIDA Y, NADLER JL, IMAI Y, MORRIS MA. Expression pattern of 12-lipoxygenase in human islets with type 1 diabetes and type 2 diabetes. J Clin Endocrinol Metab 2015: 100: E387–E395.

37. SKYLER JS. Prevention and reversal of type 1 diabetes – past challenges and future opportunities. Diabetes Care 2015: 38: 997–1007.

38. MEIER JJ, BHUSHAN A, BUTLER AE, RIZZA RA, BUTLER PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005: 48: 2221–2228.

39. MEIER JJ, RITZEL RA, MAEDLER K, GURLO T, BUTLER PC. Increased vulnerability of newly forming beta cells to cytokine-induced cell death. Diabetologia 2005: 49: 83–89.

40. KEENAN HA, SUN JK, LEVINE J et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010: 59: 2846–2853.

41. COPPIETERS KT, WIBERG A, AMIRAN N, KAY TW, VON HERRATH MG. Persistent glucose transporter expression on pancreatic beta cells from long-standing type 1 diabetic individuals. Diabetes Metab Res Rev 2011: 27: 746–754.

42. GIANANI R, CAMPBELL-THOMPSON M, SARKAR SA et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010: 53: 690–698.

43. TSAI EB, SHERRY NA, PALMER JP, HEROLD KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006: 49: 261–270.

44. SHERRY NA, TSAI EB, HEROLD KC. Natural history of [beta]-cell function in type 1 diabetes. Diabetes 2005: 54 (Suppl. 2): S32–S39.

45. GREENBAUM CJ, ANDERSON AM, DOLAN LM et al. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009: 32: 1839–1844.

46. GREENBAUM CJ, BEAM CA, BOULWARE D et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012: 61: 2066–2073.

47. SHERR JL, GHAZI T, WURTZ A, RINK L, HEROLD KC. Characterization of residual beta cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev 2014: 30: 154–162.

48. ORMAR RA, JONES AG, BESSER RE et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014: 57: 187–191.

49. WANG L, LOVEJOY NF, FAUSTMAN DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012: 35: 465–470.

50. ORAM RA, MCDONALD TJ, SHIELDS BM et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 2015: 38: 323–328.

51. SOSENKO JM, PALMER JP, GREENBAUM CJ et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006: 29: 643–649.

52. FERRANNINI E, MARI A, NOFRA TE, SOSENKO JM, SKYLER JS. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 2010: 59: 679–685.

53. SOSENKO JM, SKYLER JS, KRISCHER JP et al. Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes 2010: 59: 2386–2389.

54. DIEDISHEIM M, MALLONE R, BOITARD C, LARGER E. Beta-cell mass in non-diabetic autoantibody-positive subjects: an analysis based on the nPOD database. J Clin Endocrinol Metab 2016: 101: 1390–1397.

55. HEROLD KC, USMANI-BROWN S, GHAZI T et al. Beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 2015: 125: 1163–1173.

56. REINER T, THURBER G, GAGLIA J et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci USA 2011: 108: 12815–12820.

57. GAGLIA JL, GUIMARAES AR, HARSINGHANI M et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011: 121: 442–445.

58. GIANANI R, PUTNAM A, STILL T et al. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab 2006: 91: 1855–1861.

59. TAURIAINE N, SALMELA K, RANTALA I, KNIP M, HYOTY H. Collecting high-quality pancreatic tissue for experimental study from organ donors with signs of beta-cell autoimmunity. Diabetes Metab Res Rev 2010: 26: 585–592.

60. OIKARINEN M, TAURIAINE N, HONKANEN T et al. Analysis of pancreas tissue in a child positive for type 1 diabetes-associated autoantibodies. J Pediatr Diabetes 2008: 51: 1796–1802.

61. IN'T VELD P, LIEVEN S, DE GRUISE J et al. Screening for insulinitis in adult autoantibody-positive organ donors. Diabetes 2007: 56: 2400–2404.

62. WIBERG A, GRANSTAM A, INGVAST S et al. Characterization of human organ donors testing positive for type 1 diabetes-associated autoantibodies. Clin Exp Immunol 2015: 182: 278–288.